Cenexi recovery, new product launches and capacity additions power Gland Pharma outlook
Gland Pharma reported robust Q4 FY26 consolidated net profit of ₹366.7 crore, a 96.6% year-on-year increase, with revenue rising 22.3% to ₹1,742.8 crore, driven by strong performance in its injectables business and CDMO operations. The company's positive outlook is further strengthened by the recovery of its European unit Cenexi, planned new product launches, and significant capacity expansion, including a 250% increase in GLP-1 production. A final dividend of ₹20 per share for FY26 has also been proposed, with a record date of August 11, 2026.
May 21 2026 06:05:00
Gland Pharma shares gain most in nearly three years after Q4 results, brokerage upgrade
Gland Pharma reported a robust financial performance for Q4 FY26, with its consolidated net profit surging by 96.6% year-on-year to ₹366.68 crore and revenue from operations increasing by 22.3% to ₹1,742.79 crore. This strong performance, attributed to higher revenues and improved operating leverage, resulted in a significant positive reaction in the company's shares. The board also recommended a final dividend of ₹20 per share.
May 18 2026 10:05:00
Gland Pharma shares jump 11% as Q4 profit soars 97% YoY, co announces Rs 20/share final dividend
Gland Pharma reported a 97% year-on-year surge in its Q4 FY26 consolidated net profit, reaching ₹366.7 crore, primarily driven by strong growth in its CDMO business and improved operational efficiency. Following these robust results, the company also announced a final dividend of ₹20 per share.
May 18 2026 10:05:00
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Gland Pharma has uploaded the audio recording of its Q4 FY26 earnings call, which took place on May 15, 2026, to its official website for investor access.
May 15 2026 21:05:00
Gland Pharma Ltd - 543245 - Board Fixes Record Date Of August 11, 2026 For The Final Dividend
Gland Pharma has fixed August 11, 2026, as the Record Date for its final dividend of ₹20 per equity share for FY26. Shareholders as of this date will be eligible, with payment due within 30 days after the August 25, 2026 AGM.
May 15 2026 16:05:00
Gland Pharma Ltd - 543245 - Corporate Action-Board approves Dividend
Gland Pharma Board recommended a final dividend of ₹20 per equity share for FY26. The record date is August 11, 2026, with payment due within 30 days of the AGM.
May 15 2026 16:05:00
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Gland Pharma reported strong Q4 FY26 results with consolidated revenue increasing 22% YoY to Rs.17,428 Mn. Adjusted net profit saw a significant rise of 97% YoY to Rs.3,667 Mn, driven by robust performance across segments.
May 15 2026 16:05:00
Gland Pharma Ltd - 543245 - Board Meeting Outcome for Outcome Of Board Meeting - 15052026
Gland Pharma reported strong Q4 FY26 cons. revenue of ₹17,428 Mn, marking a 22% YoY increase, and net profit of ₹3,667 Mn, up 97% YoY. The company's board also recommended a final dividend of ₹20 per equity share for FY26.
May 15 2026 16:05:00
Gland Pharma Ltd - 543245 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Gland Pharma shareholders passed a special resolution to reappoint Ms. Naina Lal Kidwai as an Independent Director with 94.18% votes in favour. The approval also includes her remuneration as commission on profits.
May 14 2026 18:05:00
Gland Pharma Ltd - 543245 - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Gland Pharma shareholders passed a special resolution to reappoint Ms. Naina Lal Kidwai as an Independent Director with 94.18% votes in favour. The approval also includes her remuneration as commission on profits.
May 14 2026 18:05:00
Read More